Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
Not yet recruiting · NCT07730125 · Registry updated 2026-10-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | Disease Attributes, Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder, skin disorder, triple-negative breast carcinoma | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-02 | NCT07730125 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Baylor College of Medicine | 267 |
| CoRegen, Inc. | 1 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||